Lilly's TOGETHER AMPLIFY-PsO Trial: How Biologic + Peptide Combination Therapy Could Reshape Metabolic-Inflammatory Care

Chronic wound care is increasingly a multisystem discipline. Patients with plaque psoriasis, obesity, and type 2 diabetes often arrive at wound centers with overlapping inflammatory and metabolic drivers that slow healing. The emerging model of combining a biologic that targets IL-17 inflammation with an incretin peptide that targets weight and glucose metabolism represents a deliberate attempt to treat both axes at once. Lilly's TOGETHER AMPLIFY-PsO trial is examining this approach in adults with moderate-to-severe plaque psoriasis and obesity or overweight, and its design signals a broader shift in how clinicians may manage metabolic-inflammatory disease.

The Metabolic-Inflammatory Overlap in Wound Care Practice

Plaque psoriasis is not merely a skin disease. It sits within a cluster of conditions driven by systemic inflammation and metabolic dysregulation, including obesity and type 2 diabetes. For wound care physicians, podiatrists, and orthopedic surgeons, this overlap is clinically visible: patients with poorly controlled metabolic disease often present with delayed wound healing, recurrent infection, and refractory skin breakdown.

A 2025 Lancet Diabetes & Endocrinology Commission redefined clinical obesity as a chronic systemic illness in which excess adiposity directly alters tissue and organ function, with the potential to cause end-organ damage. The Commission emphasized that BMI alone is an inadequate individual measure of health and that clinicians should confirm excess adiposity with direct body-fat measurement or additional anthropometric criteria such as waist circumference, waist-to-hip ratio, or waist-to-height ratio (PMID: 39824205). For wound care teams, this reframing supports a more nuanced metabolic assessment at intake rather than relying on a single number.

Meanwhile, the 2022 ADA/EASD consensus on hyperglycemia management in type 2 diabetes places greater emphasis on weight management, social determinants of health, and the cardiorenal protective effects of GLP-1 receptor agonists and SGLT2 inhibitors (PMID: 36148880). The consensus treats glycemic control as one component of a larger metabolic strategy, not the sole endpoint.

What Biologic + Peptide Combination Therapy Represents

The combination of ixekizumab, an IL-17A biologic, with tirzepatide, a dual GIP and GLP-1 receptor agonist, is conceptually different from sequential monotherapy. The biologic targets the inflammatory cytokine pathway that underlies psoriatic skin disease. The peptide targets the incretin pathway that regulates appetite, satiety, and glycemic control. Used together, they aim to reduce skin inflammation while improving the metabolic environment that aggravates both psoriasis and wound risk.

The ADA/EASD consensus already supports GLP-1 receptor agonists as a central component of type 2 diabetes management, particularly for patients at high cardiorenal risk (PMID: 36148880). Although the consensus does not address psoriasis specifically, its framework aligns with the rationale for adding an incretin agent to a biologic: both conditions share inflammatory and vascular biology, and improving metabolic control can be expected to affect downstream tissue outcomes.

This does not mean every patient with psoriasis needs tirzepatide, or that the combination replaces local wound care. It does mean that the boundary between dermatology, endocrinology, and wound care is becoming less distinct, and that coordination across specialties is increasingly important.

Protocol and Safety Considerations

Adding an incretin peptide to a biologic requires a structured protocol. The most common adverse events with GLP-1 receptor agonists are gastrointestinal: nausea, vomiting, diarrhea, and constipation. A multidisciplinary expert consensus on managing these adverse events recommends slow dose escalation, dietary counseling, and clear criteria for when to pause or adjust dosing (PMID: 36614945). For wound care teams that already monitor nutrition, medication adherence, and glycemic status, integrating these checks into the standard visit is a natural extension.

Continuous glucose monitoring (CGM) is another tool that fits into this protocol. An international consensus on CGM metrics in clinical trials recommends standardized CGM-derived reporting as a complement to HbA1c, because CGM captures glycemic excursions, asymptomatic hypoglycemia, and postprandial hyperglycemia that HbA1c alone cannot (PMID: 36493795). For patients on incretin therapy with chronic wounds, CGM or structured capillary glucose monitoring can help identify glucose variability that impairs healing.

Implications for Amniotic Membrane Wound Biologics

Systemic therapies that reduce inflammation and improve metabolic control may change the wound care landscape, but they do not replace the need for local biological support. Amniotic membrane allografts provide a scaffold of extracellular matrix components, growth factors, and anti-inflammatory mediators that modulate the local wound environment. For wounds that are already stalled by chronic inflammation and impaired vascularity, AmnioAMP and Rampart allografts can be used alongside systemic optimization.

As combination biologic-peptide therapy becomes more common in patients with psoriasis and obesity, wound care clinicians will likely see more referrals in which the underlying systemic disease is being aggressively managed but the local wound remains recalcitrant. In those cases, amniotic membrane products remain a clinically reasonable option for improving the local wound bed. The goal is integration: systemic therapy for metabolic-inflammatory control, and advanced biologics for local tissue repair.

Key Takeaways

• Clinical obesity is increasingly recognized as a chronic systemic illness with direct tissue consequences, not just a BMI threshold (PMID: 39824205).
• Modern type 2 diabetes management emphasizes weight, cardiorenal protection, and the use of GLP-1 receptor agonists alongside glycemic control (PMID: 36148880).
• Biologic-plus-peptide combination therapy aims to address both inflammatory and metabolic pathways simultaneously, though real-world protocols must include monitoring for gastrointestinal adverse events (PMID: 36614945).
• CGM-derived metrics can complement HbA1c when monitoring glucose control in patients on incretin therapy (PMID: 36493795).
• Local wound management with amniotic membrane allografts remains a complementary strategy as systemic therapy evolves.